{"entity":{"id":"idea-data-ai-reimbursement-tied-to-outcomes","kind":"idea","name":"Pay for cancer AI only when it has outcome evidence, then pay properly","aka":[],"tldr":"Health systems would pay for AI tools that have shown in trials that they help patients, and pay nothing for tools that have not, giving makers a reason to run the trials.","summary":"Reimbursement for AI is haphazard: a few tools have billing codes on weak evidence, most have none, so vendors sell on workflow rather than outcomes. The proposal is a payer policy: a temporary payment for AI under coverage with evidence development while a prospective trial runs, converting to durable payment if outcome evidence is positive and ending if not, with payment levels reflecting demonstrated value. Medicare's coverage decisions for a handful of AI devices are a starting point.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (AI that is built but not validated or deployed): Wu et al., How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals (Nature Medicine 2021)","url":"https://doi.org/10.1038/s41591-021-01312-x"}],"tags":[],"related":["idea-data-prospective-ai-trials-fund"],"cancers":[],"sections":["ai-computation"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-ai-validation","b-incentive-misalignment"],"keyPapers":["paper-wu-nat-med"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Outcome-conditional reimbursement will increase the number of prospective AI trials started per year and shift the market toward tools with demonstrated benefit.","rationale":"Payment is the strongest signal to developers; where payers required evidence (e.g., for genomic tests via Medicare's MolDX), evidence generation followed.","test":"One national payer adopts the policy for two years; count AI trials initiated and tools reaching durable coverage versus the prior period.","maturity":"speculative","actor":"payer","cost":"medium","horizonYears":3},"route":"/ideas/idea-data-ai-reimbursement-tied-to-outcomes/","neighbours":{"idea":[{"id":"idea-data-prospective-ai-trials-fund","kind":"idea","name":"A dedicated fund for randomised trials of cancer AI with patient outcomes","route":"/ideas/idea-data-prospective-ai-trials-fund/"}],"section":[{"id":"ai-computation","kind":"section","name":"AI & Computation","route":"/fronts/ai-computation/"}],"bottleneck":[{"id":"b-ai-validation","kind":"bottleneck","name":"AI that is built but not validated or deployed","route":"/bottlenecks/b-ai-validation/"},{"id":"b-incentive-misalignment","kind":"bottleneck","name":"Incentives reward me-too drugs and marginal gains","route":"/bottlenecks/b-incentive-misalignment/"}],"paper":[{"id":"paper-wu-nat-med","kind":"paper","name":"How medical AI devices are evaluated: limitations and recommendations from an analysis of FDA approvals","route":"/key-papers/paper-wu-nat-med/"}]}}